Passage Bio, Inc. (PASG)
3.46
-0.05
(-1.42%)
USD |
NASDAQ |
Nov 05, 16:00
Passage Bio Net Income (Quarterly) : -7.821M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.821M |
| March 31, 2026 | -7.559M |
| December 31, 2025 | -12.98M |
| September 30, 2025 | -7.749M |
| June 30, 2025 | -9.385M |
| March 31, 2025 | -15.40M |
| December 31, 2024 | -12.72M |
| September 30, 2024 | -19.34M |
| June 30, 2024 | -15.99M |
| March 31, 2024 | -16.71M |
| December 31, 2023 | -16.76M |
| September 30, 2023 | -27.11M |
| June 30, 2023 | -23.86M |
| March 31, 2023 | -34.34M |
| December 31, 2022 | -27.07M |
| September 30, 2022 | -26.70M |
| Date | Value |
|---|---|
| June 30, 2022 | -39.54M |
| March 31, 2022 | -42.81M |
| December 31, 2021 | -51.15M |
| September 30, 2021 | -46.92M |
| June 30, 2021 | -48.44M |
| March 31, 2021 | -38.88M |
| December 31, 2020 | -38.94M |
| September 30, 2020 | -28.53M |
| June 30, 2020 | -27.17M |
| March 31, 2020 | -17.58M |
| December 31, 2019 | -13.15M |
| September 30, 2019 | -11.39M |
| June 30, 2019 | -13.43M |
| March 31, 2019 | -7.669M |
| December 31, 2018 | -5.819M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 7.821M |
| EPS Diluted (Quarterly) | -2.437 |
| Enterprise Value | -13.02M |
| Earnings Yield | -326.9% |
| Normalized Earnings Yield | -320.89 |